Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)


Interview Clean Logistics: Hydrogen challenge to Daimler + Co.

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".

Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".

04. March 2020 | 07:27 CET

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

  • Medical
Photo credits:

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector has become a particularly important sector. In addition to the desire for a long life with health and care, there is also an increasing demand for products and therapies that can fulfil couples' desire to have children. There is a broad spectrum and as an investor it is worth taking a look at the companies.

time to read: 1 minutes by Mario Hose
ISIN: DE000A1X3W00 , AU000000MEM5 , NL0012169213



Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author

In the fight against cancer

The name Medigene is certainly known to many traders. The German biotech company is engaged in therapies for the treatment of various types of cancer in different stages. The T-cell-focused immune therapies are the focus of Medigene. Starting in the field of blood cancers, the company is pursuing a strategy of initiating its own clinical development programmes.

In addition, therapeutic approaches are being sought with selected partners to enable successful treatment of tumors. The market value of Medigene is currently around EUR 110 million. The Medigene share is an investment in cancer research.

Increasing the chances of having children

More and more couples worldwide are desperately longing in vain for a child of their own. Modern medicine has developed various possibilities and procedures to successfully initiate pregnancy. The so-called in vitro fertilisation, also known as IVF procedure, is one possibility of artificial insemination. In this procedure, the ovum is taken from the woman and then artificially fertilized with the man's sperm in the laboratory. If the fertilization is successful, the embryos can then be transferred to the uterus so that pregnancy can begin.

In order to increase the chances of a successful pregnancy, the separation of high-quality sperm is purposeful. The Australian company Memphasys has developed a product that can be used to process the seminal fluid to increase the birth rate. The product called FELIX is currently being tested by experts and sales are expected to start in the second half of 2020. Memphasys currently has a market value of around EUR 25 million. The Memphasys shares enable investors to support couples' desire to have children and benefit from the success of the product.

Expert in molecular information

In connection with the current corona virus, the biotech company Qiagen can offer test solutions that can diagnose whether a patient is infected within an hour. The company is represented in 25 countries around the globe and employs 4,700 people.

According to Medigene, the company offers 500 products that enable physicians, scientists and laboratory staff to examine and research the molecules of the human body for various purposes. The company has more than 500,000 customers in its more than 30-year history. The market value of Qiagen is currently EUR 7.3 billion. Qiagen's stock is the focus of the hype surrounding the current corona virus and a takeover bid by Thermo Fisher. Investors can see price gains.


Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

09. December 2020 | 14:16 CET | by Nico Popp

Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?

  • Medical

The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrialized countries. Nevertheless, question marks remain: How long a vaccination will protect a person remains to be seen. For this reason, drugs and other measures to treat patients successfully remain essential. One of these drugs has just received approval from the Canadian regulatory authorities.


05. May 2020 | 08:33 CET | by Mario Hose

Evotec, Medigene, Memphasys - the right investment timing

  • Medical

The health sector has been in the focus of investors not only since the outbreak of the corona pandemic. The pursuit of a healthy and long life is the motivation for research and development around the globe. In addition to Europe and the USA, Australia as a continent is also a location for ideas and innovations. Investors usually always ask the same questions. How expensive and how long does it take to develop the drug or solution and how big is the market. The bigger the problem or need to be treated, the more lucrative it is.


24. April 2020 | 07:36 CET | by Mario Hose

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

  • Medical

There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.